Object. Nelson's syndrome (NS) is a significant and frequent risk for patients with Cushing's disease (CD) who undergo bilateral adrenalectomy. A recent study has shown tumor progression in 47% of patients at risk for NS. The authors sought to define the rate of NS in patients who were treated with Gamma Knife stereotactic radiosurgery (GK SRS) prior to bilateral adrenalectomy.
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B ilateral adrenalectomy is the definitive treatment for patients with CD that is unresponsive to therapy directed at the pituitary. 21 A significant proportion of these patients develop NS, or enlargement of residual pituitary tumor due to removal of the negative feedback effect of cortisol. 17, 18 Rapid, unchecked tumor growth may cause local mass effect and significant morbidity. Large case series have defined the incidence of NS as 8%-29%, occurring up to 24 years after bilateral adrenalectomy. 7, 8, 11, 12, [14] [15] [16] 19, 21, 23 Historically, the diagnosis of NS has been made using clinical criteria. A recent study in which modern MRI techniques were used has demonstrated that the rate of tumor growth is probably underappreciated and occurs in 47% of patients by 7 years. 1 In our clinical experience at a tertiary referral center for CD, we have observed a lower incidence of NS than has been reported previously. Our management protocol differs from other institutions in that patients who do not achieve remission after pituitary surgery undergo sellar irradiation with GK SRS prior to bilateral adrenalectomy. Conventional radiation has been suggested to have an effect on the rate of NS after adrenalectomy; however, not all studies have confirmed this association. 7, 11, 15, 16, 19, 23 We postulated that preoperative SRS could explain our observed reduced rate of NS. To date, no study has determined the rate of NS when SRS has been used. Furthermore, the relationship between radiation and the development of NS has not been defined using modern MRI techniques, as suggested by Assié and colleagues.
1 Therefore, we sought to define the incidence of NS in our cohort of patients who underwent GK SRS prior to bilateral adrenalectomy; careful follow-up with modern MRI techniques was performed.
Methods

Patient Population
Patients with confirmed CD who had persistently elevated cortisol despite transsphenoidal pituitary surgery and subsequent pituitary GK SRS, and who later underwent bilateral adrenalectomy for significant persistent disease at the University of Virginia were included. Patients Effect of stereotactic radiosurgery before bilateral adrenalectomy for Cushing's disease on the incidence of Nelson's syndrome with less than 6 months of neuroimaging follow-up were excluded. Institutional review board approval was obtained before initiation of the study.
Radiosurgery Details
Sellar irradiation was performed using a cobalt-60 Elekta Gamma Knife unit as previously described.
14 Treatment plans were based on thin-slice MRI studies obtained before and after contrast administration after placement of the Leksell model G stereotactic frame (Elekta, Inc.). Dose plans were generated by a multidisciplinary team consisting of a neurosurgeon, a radiation oncologist, and a medical physicist. The number of isocenters, maximum radiation dose, prescribed dose to the tumor margins, and treatment isodose were recorded.
Imaging Studies
Pretreatment and posttreatment T1-weighted MRI studies of the pituitary were obtained at regular intervals. A neuroradiologist independently interpreted all studies. The MRI impressions were then categorized as consistent with tumor growth when the tumor exceeded 10% of its original volume; no change when the tumor was within ± 10% of its original volume; tumor regression when the tumor decreased by more than 10% of its original volume but was still visible; or no tumor visible. 6, 22 We routinely obtained MRI studies at 6-month intervals for the first 2 years after GK SRS and then yearly thereafter.
Clinical Evaluation
Patients were evaluated clinically at 6-month intervals for the first 2 years after GK SRS and then yearly thereafter to confirm remission, to evaluate for NS, and to manage hormone replacement. As part of this endocrine evaluation, serum ACTH, cortisol, thyroid stimulating hormone, free thyroxine, and insulin-like growth factor-I levels were routinely obtained. Serum testosterone levels were followed in men and menstrual function was monitored in premenopausal women. Specific to NS, patients were clinically evaluated for hyperpigmentation, visual changes, and cranial neuropathy.
Statistical Analysis
Given the recent findings by Assié and colleagues, 1 corticotroph tumor growth was considered the most sensitive measure of treatment failure and therefore was the primary end point. The Fisher exact test was used to assess the relationship between categorical variables and corticotroph tumor growth during the follow-up after bilateral adrenalectomy. For continuous predictors, univariate logistic regression was performed. Survival analyses were used to evaluate the time-to-event data and determine progression-free survival. Start time was defined as the time at which bilateral adrenalectomy was performed, and event time was recorded as the time at which corticotroph tumor growth was first noted. The 2-sample ttest was used to compare the means of sets of continuous variables, using a boxplot to determine if variance was equivalent. Statistical analyses were done using the software R (R version 2.7.2, The R Foundation for Statistical Computing). Statistical significance was determined by a 2-sided p value < 0.05.
Results
Patient Characteristics
Twenty patients (17 women and 3 men) met the inclusion criteria for the study (Table 1) . Four patients with neuroimaging follow-up of less than 6 months were not included. All patients received a diagnosis of CD and underwent one or more transsphenoidal operations to remove an ACTH-secreting tumor from the pituitary gland. Four patients (20%) underwent a total hypophysectomy. Patients either had unresectable residual tumor (11 patients, 55%) or persistently elevated cortisol despite no clear microadenoma on pituitary MRI studies (9 patients, 45%).
Treatment Characteristics
All patients underwent GK SRS at the University of Virginia. The sellar target was treated with a mean margin dose of 24 Gy (range 18-30 Gy). A mean of 6 isocenters (range 2-17) were used. All patients had persistence of hypercortisolemia. Four cases (20%) initially improved, but later developed recurrent hypercortisolemia and underwent repeat GK SRS with a mean margin dose of 23 Gy (range 20-25 Gy). The time between initial and repeat GK SRS varied from 2.6 to 10 years. All 4 patients developed recurrent hypercortisolemia after this second treatment.
After failure of surgical and radiosurgical treatment directed at the pituitary, patients with significant persistent disease underwent bilateral adrenalectomy at the University of Virginia. Adrenalectomy was performed a median of 1.5 years (range 2 days-9.7 years) after the most recent GK SRS procedure. Although GK SRS may take several years to result in endocrine remission in CD, the majority of these patients had uncontrolled CD with significant morbidity, and therefore could no longer wait for the latency of GK SRS. 9 
Radiological Outcomes
Patient outcomes were determined using MRI studies obtained at regular intervals, with a median neuroimaging follow-up of 5.4 years (range 0.6-12 years). In 15 cases (75%) no tumor was visible on any of the serial scans. In 4 cases (20%), visible residual tumor at the time of bilateral adrenalectomy was stable throughout follow-up. One patient (5%) demonstrated new tumor growth on follow-up imaging 9 months after bilateral adrenalectomy and was considered to have developed NS (Fig. 1) . This patient was treated with GK SRS focused on the new growth and was started on cabergoline pharmacotherapy. At last followup, the tumor was no longer visible on neuroimaging studies throughout an additional 8.5 years of evaluation.
By Kaplan-Meier analysis, progression-free survival rates at 1, 3, and 7 years were each 94.7% (number of patients at risk: 18, 12, and 5, respectively) (Fig. 2) . Using univariate analysis, clinical factors were evaluated for their effect on tumor growth. Age, sex, time from radiosurgery to adrenalectomy, length of follow-up, treatment of residual tumor, prior total hypophysectomy, margin dose, or a second GK SRS did not significantly predict tumor progression (Table 2) .
Clinical and Endocrinological Outcomes
Clinical and endocrine follow-up was available for 18 patients. Patients had a median clinical follow-up of 5.2 years (range 1.5-12 years). No patient demonstrated evidence of hypercortisolemia. Eleven (61%) of these 18 patients developed ACTH levels greater than 200 pg/ml and 4 patients (22%) developed levels greater than 1000 pg/ml during follow-up (mean maximum ACTH: 314 pg/ ml, range 11-1598 pg/ml) (Fig. 3) . The patient with MRIconfirmed tumor growth developed a maximum ACTH of 1285 pg/ml. After repeat GK SRS, ACTH levels in this patient fell to less than 100 pg/ml, but have recently increased to levels greater than 1000 pg/ml despite negative MRI findings. Six patients (33%) developed hyperpigmentation, which was significantly more likely in patients with higher plasma ACTH levels during follow-up (p = 0.04). There were no clinical signs of tumor growth noted, including new cranial neuropathy or visual deficits.
Complications of Radiosurgery
No patient developed new cranial neuropathy or visual deficit after GK SRS. Ten patients (50%) had residual pituitary function prior to GK SRS. Of these patients, 2 (20%) developed new hypothyroidism in the follow-up period after GK SRS. No other new endocrinopathy was noted. No evidence of postradiosurgery carotid ischemia, carotid stenosis, or radiation-induced neoplasia was seen on follow-up MRI studies.
Discussion
Cushing's disease is among the most challenging endocrine disorders to manage. First-line therapy is pituitary surgery, which can be curative in a large number of patients. 10 Cases not cured by surgery often require multimodality management consisting of radiation and medical therapies, including steroidogenesis inhibitors such as ketoconazole and metyrapone.
2 If these measures fail to achieve remission, then bilateral adrenalectomy can be used for definitive elimination of cortisol secretion. Although the morbidity of this procedure has diminished with improving techniques, postoperative patients still re quire lifetime mineralocorticoid and glucocorticoid replacement and are at risk for developing NS. 21 
Nelson's Syndrome
In 1958, Don Nelson and colleagues 17 reported on a patient with Cushing's syndrome who underwent bilateral adrenalectomy in 1954, and developed cutaneous hyperpigmentation, amenorrhea, bitemporal visual loss, and rising plasma ACTH values over the following 3 years. She was found to have an expanded sella turcica on skull films and a large pituitary adenoma at subsequent surgery. In 1960, Nelson and coworkers 18 reported similar findings in 9 additional patients. The eponymous Nelson's syndrome is now a well-recognized risk of bilateral adrenalectomy; 2, 7, 8, 11, 12, 15, 16, 19, 21, 23 NS can cause significant morbidity due to rapid, unchecked tumor growth and local mass effect, and occurs after 8%-29% of cases of bilateral adrenalectomy. Long-term surveillance is critical, because clinical symptoms have been reported as many as 24 years after adrenalectomy. 16 A recent study demonstrated that tumor growth after bilateral adrenalectomy is an underreported phenomenon.
1
Although NS has long been defined by clinical presentation, Assié and colleagues used modern pituitary MRI techniques to identify the incidence of tumor growth after adrenalectomy, the underlying cause of NS. With a median follow-up of 4.6 years, the incidence of tumor growth in this cohort was 39% at 3 years and 47% at 7 years.
Prior studies have attempted to identify factors that predict development of NS. Young age at adrenalectomy and a documented pituitary adenoma at surgery have been identified as predisposing factors in some studies. 8, 11, 12, 23 Conventional pituitary irradiation before bilateral adrenalectomy has also been associated with a reduced incidence of NS by some authors. 7, 11, 16 The definition of NS varied among these studies, with some authors determining outcome on the basis of elevated ACTH levels and hyperpigmentation alone. 11 Other studies that have assessed the effect of pituitary irradiation on the development of NS have found no influence.
15,19,23
Gamma Knife SRS for CD
Radiation therapy is an important treatment modality in the management of CD. A recent consensus statement by the Endocrine Society on the management of CD defined pituitary radiotherapy as second-line therapy after transsphenoidal surgery, with control of hypercortisolemia achieved in 50%-60% of patients.
2 Although different from fractionated radiation therapy, GK SRS does use ionizing radiation in a fashion that limits radiation exposure to the surrounding critical neurovascular structures. Modern, long-term series have shown that GK SRS is effective in achieving remission in 42%-87% of patients in whom transsphenoidal surgery failed. 3, 9, 20 Radiosurgery also appears to induce a faster endocrine remission compared with radiation therapy. 13 Potential risks of GK SRS have been defined by these and other large series and include hypopituitarism (20%-23%) and cranial neuropathy (4%).
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Gamma Knife SRS and NS
In addition to having a biological effect on primary lesions in CD, GK SRS can also control the lesions that develop with NS. Several recent studies have found that GK SRS controls tumor growth in 82%-100% of patients who develop NS lesions. 14, 20, 24 No study, however, has assessed the effect of GK SRS performed before bilateral adrenalectomy on the incidence of NS. Additionally, although conventional pituitary radiation before adrenalectomy has, in some cases, been shown to decrease the rate of NS, this relationship has not been analyzed using sensitive MRI techniques to detect subclinical tumor development. 7, 11, 16 Our study demonstrates that the use of GK SRS before bilateral adrenalectomy reduces the rate of NS (5.3% at 3 and 7 years by Kaplan-Meier analysis) when using MRI sequences to detect tumor growth, compared with historical controls. Assié and colleagues 1 found the rate of tumor growth after bilateral adrenalectomy to be 39% and 47% at 3 and 7 years, respectively, and did not include patients who received pituitary radiotherapy. Our series includes longer follow-up (median 5.4 years compared with 4.7 years) but fewer patients (20 patients compared with 47 patients).
In our study, no specific preoperative factors predict which patients will benefit from GK SRS. This univariate analysis may be limited by the observation that only 1 patient had tumor growth. Additionally, multivariate analysis is not appropriate given the paucity of instances of tumor growth. 5 Because NS is a rare clinical entity and the rate of events in patients treated with GK SRS is relatively low (5.3%), adequate analysis of predisposing factors would re quire a multicenter study. Additionally, because this is 3 . Graphic representation of initial (prior to adrenalectomy) and maximum ACTH levels during follow-up in 18 patients. The ACTH levels typically increased during follow-up. Eleven (61%) and 4 (22%) patients developed maximum ACTH levels greater than 200 and 1000 pg/ml, respectively. The patient who developed NS (dashed line) did not have ACTH testing before adrenalectomy, but developed rising ACTH levels and tumor growth after treatment, which responded to repeat GK SRS (asterisk).
a retrospective study it is subject to inherent biases, and this population may be studied prospectively in the future.
Overall, GK SRS was well tolerated in this cohort, with the rate of new endocrinopathy in patients with residual pituitary function (20%) similar to previously pub lished results for CD. 3, 9 Additionally, no cranial neuropathy was noted, reinforcing the previously described neurovascular safety profile of this technique. 4 Therefore, par tic ularly in patients with panhypopituitarism who have un der gone total or subtotal hypophysectomy, GK SRS may be used with minimal risk of complications.
Conclusions
Nelson's syndrome is a potentially devastating complication of bilateral adrenalectomy for CD. The present study demonstrates that GK SRS appears to have the benefit of reducing the incidence of NS after bilateral adrenalectomy in the cases in which it fails to achieve remission. These results suggest that in addition to being a safe and effective second-line approach for CD, GK SRS also serves as durable prophylaxis for NS. Therefore, GK SRS should be considered before bilateral adrenalectomy in the management of CD.
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